|
|
 Previous Article | Table of Contents | Next Article 
Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in
vivo
C Sgadari, JM Farber, AL Angiolillo, F Liao, J Teruya-Feldstein, PR Burd, L Yao, G Gupta, C Kanegane and G Tosato
Center for Biologics Evaluation and Research, Bethesda, MD 20892, USA.
Mig, the monokine induced by interferon-gamma, is a CXC chemokine active as
a chemoattractant for activated T cells. Mig is related functionally to
interferon-inducible protein 10 (IP-10), with which it shares a receptor,
CXCR3. Previously, IP-10 was found to have antitumor activity in vivo. In
the present study, murine Mig RNA was found to be expressed at higher
levels in regressing Burkitt's lymphoma tumors established in nude mice
compared with progressively growing tumors. Daily inoculations of purified
recombinant human Mig into Burkitt's tumors growing subcutaneously in nude
mice consistently caused tumor necrosis associated with extensive vascular
damage. These effects were indistinguishable from those produced by
intratumor inoculations of Burkitt's tumors with IP-10. These results
support the notion that Mig, like IP-10, has antitumor activity in vivo.
Volume 89,
Issue 8,
pp. 2635-2643,
04/15/1997
Copyright © 1997 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. F. Little, K. Aleman, P. Kumar, K. M. Wyvill, J. M. Pluda, E. Read-Connole, V. Wang, S. Pittaluga, A. T. Catanzaro, S. M. Steinberg, et al.
Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma
Blood,
December 15, 2007;
110(13):
4165 - 4171.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Del Vecchio, E. Bajetta, S. Canova, M. T. Lotze, A. Wesa, G. Parmiani, and A. Anichini
Interleukin-12: Biological Properties and Clinical Application
Clin. Cancer Res.,
August 15, 2007;
13(16):
4677 - 4685.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ramirez-Montagut, A. Chow, A. A. Kochman, O. M. Smith, D. Suh, H. Sindhi, S. Lu, C. Borsotti, J. Grubin, N. Patel, et al.
IFN-{gamma} and Fas Ligand Are Required for Graft-versus-Tumor Activity against Renal Cell Carcinoma in the Absence of Lethal Graft-versus-Host Disease
J. Immunol.,
August 1, 2007;
179(3):
1669 - 1680.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. V. Gorbachev, H. Kobayashi, D. Kudo, C. S. Tannenbaum, J. H. Finke, S. Shu, J. M. Farber, and R. L. Fairchild
CXC Chemokine Ligand 9/Monokine Induced by IFN-{gamma} Production by Tumor Cells Is Critical for T Cell-Mediated Suppression of Cutaneous Tumors
J. Immunol.,
February 15, 2007;
178(4):
2278 - 2286.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Hong, H. Lee, M. Oh, C.-Y. Kang, S. Hong, and S.-H. Park
CD4+ T Cells in the Absence of the CD8+ Cytotoxic T Cells Are Critical and Sufficient for NKT Cell-Dependent Tumor Rejection
J. Immunol.,
November 15, 2006;
177(10):
6747 - 6757.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Nelson and R. Ganss
Tumor growth or regression: powered by inflammation
J. Leukoc. Biol.,
October 1, 2006;
80(4):
685 - 690.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. N. Gomperts and R. M. Strieter
CXC Chemokines in Angiogenesis and Metastases
Am. Assoc. Cancer Res. Educ. Book,
April 1, 2006;
2006(1):
11 - 18.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Bodnar, C. C. Yates, and A. Wells
IP-10 Blocks Vascular Endothelial Growth Factor-Induced Endothelial Cell Motility and Tube Formation via Inhibition of Calpain
Circ. Res.,
March 17, 2006;
98(5):
617 - 625.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Numasaki, M. Watanabe, T. Suzuki, H. Takahashi, A. Nakamura, F. McAllister, T. Hishinuma, J. Goto, M. T. Lotze, J. K. Kolls, et al.
IL-17 Enhances the Net Angiogenic Activity and In Vivo Growth of Human Non-Small Cell Lung Cancer in SCID Mice through Promoting CXCR-2-Dependent Angiogenesis
J. Immunol.,
November 1, 2005;
175(9):
6177 - 6189.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. G. Galvez, L. Genis, S. Matias-Roman, S. A. Oblander, K. Tryggvason, S. S. Apte, and A. G. Arroyo
Membrane Type 1-Matrix Metalloproteinase Is Regulated by Chemokines Monocyte-Chemoattractant Protein-1/CCL2 and Interleukin-8/CXCL8 in Endothelial Cells during Angiogenesis
J. Biol. Chem.,
January 14, 2005;
280(2):
1292 - 1298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. B. Dickerson, N. Akhtar, H. Steinberg, Z.-Y. Wang, M. J. Lindstrom, M. L. Padilla, R. Auerbach, and S. C. Helfand
Enhancement of the Antiangiogenic Activity of Interleukin-12 by Peptide Targeted Delivery of the Cytokine to {alpha}v{beta}3 Integrin
Mol. Cancer Res.,
December 1, 2004;
2(12):
663 - 673.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kawada, M. Sonoshita, H. Sakashita, A. Takabayashi, Y. Yamaoka, T. Manabe, K. Inaba, N. Minato, M. Oshima, and M. M. Taketo
Pivotal Role of CXCR3 in Melanoma Cell Metastasis to Lymph Nodes
Cancer Res.,
June 1, 2004;
64(11):
4010 - 4017.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-C. Yang, S. Hillinger, K. Riedl, L. Zhang, L. Zhu, M. Huang, K. Atianzar, B. Y. Kuo, B. Gardner, R. K. Batra, et al.
Intratumoral Administration of Dendritic Cells Overexpressing CCL21 Generates Systemic Antitumor Responses and Confers Tumor Immunity
Clin. Cancer Res.,
April 15, 2004;
10(8):
2891 - 2901.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Hillinger, S.-C. Yang, L. Zhu, M. Huang, R. Duckett, K. Atianzar, R. K. Batra, R. M. Strieter, S. M. Dubinett, and S. Sharma
EBV-Induced Molecule 1 Ligand Chemokine (ELC/CCL19) Promotes IFN-{gamma}-Dependent Antitumor Responses in a Lung Cancer Model
J. Immunol.,
December 15, 2003;
171(12):
6457 - 6465.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-Q. Gao, Y. Tsuda, K. Katayama, T. Nakayama, Y. Hatanaka, Y. Tani, H. Mizuguchi, T. Hayakawa, O. Yoshie, Y. Tsutsumi, et al.
Antitumor Effect by Interleukin-11 Receptor {alpha}-Locus Chemokine/CCL27, Introduced into Tumor Cells through a Recombinant Adenovirus Vector
Cancer Res.,
August 1, 2003;
63(15):
4420 - 4425.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Qin, J. Schwartzkopff, F. Pradera, T. Kammertoens, B. Seliger, H. Pircher, and T. Blankenstein
A Critical Requirement of Interferon {gamma}-mediated Angiostasis for Tumor Rejection by CD8+ T Cells
Cancer Res.,
July 15, 2003;
63(14):
4095 - 4100.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-L. Ma, M. J. Whitters, R. F. Konz, M. Senices, D. A. Young, M. J. Grusby, M. Collins, and K. Dunussi-Joannopoulos
IL-21 Activates Both Innate and Adaptive Immunity to Generate Potent Antitumor Responses that Require Perforin but Are Independent of IFN-{gamma}
J. Immunol.,
July 15, 2003;
171(2):
608 - 615.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Lasagni, M. Francalanci, F. Annunziato, E. Lazzeri, S. Giannini, L. Cosmi, C. Sagrinati, B. Mazzinghi, C. Orlando, E. Maggi, et al.
An Alternatively Spliced Variant of CXCR3 Mediates the Inhibition of Endothelial Cell Growth Induced by IP-10, Mig, and I-TAC, and Acts as Functional Receptor for Platelet Factor 4
J. Exp. Med.,
June 2, 2003;
197(11):
1537 - 1549.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Flynn and B. Stockinger
Tumor and CD4 T-cell interactions: tumor escape as result of reciprocal inactivation
Blood,
June 1, 2003;
101(11):
4472 - 4478.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G.-S. Shin, B.-H. Lee, S. Lee, S.-Y. Chung, M. Kim, J. Lim, Y. Kim, H. J. Kwon, C. S. Kang, and K. Han
Monokine Levels in Cancer and Infection
Ann. Clin. Lab. Sci.,
April 1, 2003;
33(2):
149 - 155.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. H. Poehlein, H.-M. Hu, J. Yamada, I. Assmann, W. G. Alvord, W. J. Urba, and B. A. Fox
TNF Plays an Essential Role in Tumor Regression after Adoptive Transfer of Perforin/IFN-{gamma} Double Knockout Effector T Cells
J. Immunol.,
February 15, 2003;
170(4):
2004 - 2013.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Hess, N. K. Egilmez, N. Bailey, T. M. Anderson, E. Mathiowitz, S. H. Bernstein, and R. B. Bankert
Human CD4+ T Cells Present Within the Microenvironment of Human Lung Tumors Are Mobilized by the Local and Sustained Release of IL-12 to Kill Tumors In Situ by Indirect Effects of IFN-{gamma}
J. Immunol.,
January 1, 2003;
170(1):
400 - 412.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Hayakawa, K. Takeda, H. Yagita, M. J. Smyth, L. Van Kaer, K. Okumura, and I. Saiki
IFN-gamma -mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha -galactosylceramide
Blood,
August 13, 2002;
100(5):
1728 - 1733.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Gri, C. Chiodoni, E. Gallo, A. Stoppacciaro, F. Y. Liew, and M. P. Colombo
Antitumor Effect of Interleukin (IL)-12 in the Absence of Endogenous IFN-{gamma}: A Role for Intrinsic Tumor Immunogenicity and IL-15
Cancer Res.,
August 1, 2002;
62(15):
4390 - 4397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. K. Park, D. Amichay, P. Love, E. Wick, F. Liao, A. Grinberg, R. L. Rabin, H. H. Zhang, S. Gebeyehu, T. M. Wright, et al.
The CXC Chemokine Murine Monokine Induced by IFN-{gamma} (CXC Chemokine Ligand 9) Is Made by APCs, Targets Lymphocytes Including Activated B Cells, and Supports Antibody Responses to a Bacterial Pathogen In Vivo
J. Immunol.,
August 1, 2002;
169(3):
1433 - 1443.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Li, X. Zhang, and X. Xia
Regression of Tumor Growth and Induction of Long-Term Antitumor Memory by Interleukin 12 Electro-Gene Therapy
J Natl Cancer Inst,
May 15, 2002;
94(10):
762 - 768.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Dorsey, N. Kundu, Q. Yang, C. S. Tannenbaum, H. Sun, T. A. Hamilton, and A. M. Fulton
Immunotherapy with Interleukin-10 Depends on the CXC Chemokines Inducible Protein-10 and Monokine Induced by IFN-{gamma}
Cancer Res.,
May 1, 2002;
62(9):
2606 - 2610.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Ganss, E. Ryschich, E. Klar, B. Arnold, and G. J. Hammerling
Combination of T-Cell Therapy and Trigger of Inflammation Induces Remodeling of the Vasculature and Tumor Eradication
Cancer Res.,
March 1, 2002;
62(5):
1462 - 1470.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Ruehlmann, R. Xiang, A. G. Niethammer, Y. Ba, U. Pertl, C. S. Dolman, S. D. Gillies, and R. A. Reisfeld
MIG (CXCL9) Chemokine Gene Therapy Combines with Antibody-Cytokine Fusion Protein to Suppress Growth and Dissemination of Murine Colon Carcinoma
Cancer Res.,
December 1, 2001;
61(23):
8498 - 8503.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ibe, Z. Qin, T. Schuler, S. Preiss, and T. Blankenstein
Tumor Rejection by Disturbing Tumor Stroma Cell Interactions
J. Exp. Med.,
November 26, 2001;
194(11):
1549 - 1560.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Lamikanra, Z.-K. Pan, S. N. Isaacs, T.-C. Wu, and Y. Paterson
Regression of Established Human Papillomavirus Type 16 (HPV-16) Immortalized Tumors In Vivo by Vaccinia Viruses Expressing Different Forms of HPV-16 E7 Correlates with Enhanced CD8+ T-Cell Responses That Home to the Tumor Site
J. Virol.,
October 15, 2001;
75(20):
9654 - 9664.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Sharma, M. Stolina, L. Zhu, Y. Lin, R. Batra, M. Huang, R. Strieter, and S. M. Dubinett
Secondary Lymphoid Organ Chemokine Reduces Pulmonary Tumor Burden in Spontaneous Murine Bronchoalveolar Cell Carcinoma
Cancer Res.,
September 1, 2001;
61(17):
6406 - 6412.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Winter, H.-M. Hu, K. McClain, W. J. Urba, and B. A. Fox
Immunotherapy of Melanoma: A Dichotomy in the Requirement for IFN-{{gamma}} in Vaccine-Induced Antitumor Immunity Versus Adoptive Immunotherapy
J. Immunol.,
June 15, 2001;
166(12):
7370 - 7380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Yao, J. Setsuda, C. Sgadari, B. Cherney, and G. Tosato
Interleukin-18 expression induced by Epstein-Barr virus-infected cells
J. Leukoc. Biol.,
May 1, 2001;
69(5):
779 - 784.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. J. Kirk, D. Hartigan-O’Connor, B. J. Nickoloff, J. S. Chamberlain, M. Giedlin, L. Aukerman, and J. J. Mulé
T Cell-dependent Antitumor Immunity Mediated by Secondary Lymphoid Tissue Chemokine: Augmentation of Dendritic Cell-based Immunotherapy
Cancer Res.,
March 1, 2001;
61(5):
2062 - 2070.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
G. L. Beatty and Y. Paterson
IFN-{{gamma}}-Dependent Inhibition of Tumor Angiogenesis by Tumor-Infiltrating CD4+ T Cells Requires Tumor Responsiveness to IFN-{{gamma}}
J. Immunol.,
February 15, 2001;
166(4):
2276 - 2282.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. T. Liu, D. Armstrong, T. A. Hamilton, and T. E. Lane
Expression of Mig (Monokine Induced by Interferon-{{gamma}}) Is Important in T Lymphocyte Recruitment and Host Defense Following Viral Infection of the Central Nervous System
J. Immunol.,
February 1, 2001;
166(3):
1790 - 1795.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. L. Beatty and Y. Paterson
IFN-{gamma} Can Promote Tumor Evasion of the Immune System In Vivo by Down-Regulating Cellular Levels of an Endogenous Tumor Antigen
J. Immunol.,
November 15, 2000;
165(10):
5502 - 5508.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Jinquan, S. Quan, H. H. Jacobi, C. Jing, A. Millner, B. Jensen, H. O. Madsen, L. P. Ryder, A. Svejgaard, H.-J. Malling, et al.
CXC chemokine receptor 3 expression on CD34+ hematopoietic progenitors from human cord blood induced by granulocyte-macrophage colony-stimulating factor: chemotaxis and adhesion induced by its ligands, interferon gamma -inducible protein 10 and monokine induced by interferon gamma
Blood,
August 15, 2000;
96(4):
1230 - 1238.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Jinquan, C. Jing, H. H. Jacobi, C. M. Reimert, A. Millner, S. Quan, J. B. Hansen, S. Dissing, H.-J. Malling, P. S. Skov, et al.
CXCR3 Expression and Activation of Eosinophils: Role of IFN-{gamma}-Inducible Protein-10 and Monokine Induced by IFN-{gamma}
J. Immunol.,
August 1, 2000;
165(3):
1548 - 1556.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Belperio, M. P. Keane, D. A. Arenberg, C. L. Addison, J. E. Ehlert, M. D. Burdick, and R. M. Strieter
CXC chemokines in angiogenesis
J. Leukoc. Biol.,
July 1, 2000;
68(1):
1 - 8.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. J. Frederick, Y. Henderson, X. Xu, M. T. Deavers, A. A. Sahin, H. Wu, D. E. Lewis, A. K. El-Naggar, and G. L. Clayman
In Vivo Expression of the Novel CXC Chemokine BRAK in Normal and Cancerous Human Tissue
Am. J. Pathol.,
June 1, 2000;
156(6):
1937 - 1950.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Sleeman, J. K. Fraser, J. G. Murison, S. L. Kelly, R. L. Prestidge, D. J. Palmer, J. D. Watson, and K. D. Kumble
B cell- and monocyte-activating chemokine (BMAC), a novel non-ELR {alpha}-chemokine
Int. Immunol.,
May 1, 2000;
12(5):
677 - 689.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
